Lemaitre Vascular Inc.
LeMaitre Vascular (Nasdaq: LMAT) develops, manufactures, and markets medical devices and human tissue cryopreservation services used mainly to treat peripheral vascular disease, end-stage renal disease, and cardiovascular disease. Its products serve vascular surgeons and, to a lesser extent, cardiac, general, and… From the company’s description.
In fiscal 2025, Lemaitre Vascular Inc. reported revenue of $249.60M, up 13.5% from fiscal 2024, and net income of $57.73M. Its operating margin was 27.2%, and operations generated $81.25M in cash. Over the twelve months to Jun 30, 2026, revenue was $262.43M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lemaitre Vascular Inc. does
In the company’s own words
LeMaitre Vascular (Nasdaq: LMAT) develops, manufactures, and markets medical devices and human tissue cryopreservation services used mainly to treat peripheral vascular disease, end-stage renal disease, and cardiovascular disease. Its products serve vascular surgeons and, to a lesser extent, cardiac, general, and neurosurgeons; most are used in open vascular surgery and dialysis access. The portfolio includes biologic grafts and patches, vascular grafts, catheters, carotid shunts, closure systems, valvulotomes, and RestoreFlow human tissue cryopreservation services. Major brands include XenoSure, Artegraft, Pruitt, Omniflow, LifeSpan, and CardioCel. The company sells primarily through a direct sales force, with distributors serving other countries; about 95% of 2025 net sales came from territories with direct sales representatives. At December 31, 2025, its sales force included 160 representatives and export managers. Founded in 1983, LeMaitre has expanded its product portfolio through acquisitions and research and development.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 1158895
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lemaitre Vascular Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lemaitre Vascular Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Lemaitre Vascular Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Lemaitre Vascular Inc.’s debt, $25.08M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.50%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lemaitre Vascular Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lemaitre Vascular Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lemaitre Vascular Inc.'s last four quarterly filings that the numbers alone won't show?”